63 related articles for article (PubMed ID: 25946855)
21. The neoplastic development of malignant melanoma. A biological rationale.
Cramer SF
Am J Dermatopathol; 1984; 6 Suppl():299-308. PubMed ID: 6528933
[TBL] [Abstract][Full Text] [Related]
22. p53R2 is a prognostic factor of melanoma and regulates proliferation and chemosensitivity of melanoma cells.
Matsushita S; Ikeda R; Fukushige T; Tajitsu Y; Gunshin K; Okumura H; Ushiyama M; Akiyama S; Kawai K; Takeda Y; Yamada K; Kanekura T
J Dermatol Sci; 2012 Oct; 68(1):19-24. PubMed ID: 22902076
[TBL] [Abstract][Full Text] [Related]
23. Expression of matrix metalloproteinase-2 and -9 and membrane-type 1 matrix metalloproteinase in melanocytic tumors of dogs and canine melanoma cell lines.
Docampo MJ; Cabrera J; Rabanal RM; Bassols A
Am J Vet Res; 2011 Aug; 72(8):1087-96. PubMed ID: 21801067
[TBL] [Abstract][Full Text] [Related]
24. Increased levels of DUSP6 phosphatase stimulate tumourigenesis in a molecularly distinct melanoma subtype.
Li W; Song L; Ritchie AM; Melton DW
Pigment Cell Melanoma Res; 2012 Mar; 25(2):188-99. PubMed ID: 22171919
[TBL] [Abstract][Full Text] [Related]
25. Detection of tyrosinase mRNA by an optimised nested RT-PCR in the peripheral blood of patients with advanced malignant melanoma.
Glumac N; Hocevar M; Snoj M; Novakovic S
J Exp Clin Cancer Res; 2001 Dec; 20(4):529-36. PubMed ID: 11876547
[TBL] [Abstract][Full Text] [Related]
26. ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839).
Djerf EA; Trinks C; Abdiu A; Thunell LK; Hallbeck AL; Walz TM
Melanoma Res; 2009 Jun; 19(3):156-66. PubMed ID: 19434003
[TBL] [Abstract][Full Text] [Related]
27. Specifying protein kinase C functions in melanoma.
Denning MF
Pigment Cell Melanoma Res; 2012 Jul; 25(4):466-76. PubMed ID: 22578192
[TBL] [Abstract][Full Text] [Related]
28. The effect of antisense tyrosinase-related protein 1 on melanocytes and malignant melanoma cells.
Li CY; Gao TW; Wang G; Han ZY; Shen Z; Li TH; Liu YF
Br J Dermatol; 2004 Jun; 150(6):1081-90. PubMed ID: 15214892
[TBL] [Abstract][Full Text] [Related]
29. The SH3 and SH2 domains are capable of directing specificity in protein interactions between the non-receptor tyrosine kinases cSrc and cYes.
Summy JM; Guappone AC; Sudol M; Flynn DC
Oncogene; 2000 Jan; 19(1):155-60. PubMed ID: 10644991
[TBL] [Abstract][Full Text] [Related]
30. [Unusual and unknown aspect of cutaneous malignant melanoma: minimal deviation malignant melanoma. Retrospective study of 45 cases].
Mérot Y; Mihm MC
Ann Dermatol Venereol; 1985; 112(4):325-36. PubMed ID: 4026131
[TBL] [Abstract][Full Text] [Related]
31. pp60c-src in human melanocytes and melanoma cells exhibits elevated specific activity and reduced tyrosine 530 phosphorylation compared to human fibroblast pp60c-src.
O'Connor TJ; Neufeld E; Bechberger J; Fujita DJ
Cell Growth Differ; 1992 Jul; 3(7):435-42. PubMed ID: 1384653
[TBL] [Abstract][Full Text] [Related]
32. Value of dopachrome tautomerase detection in the assessment of melanocytic tumors.
Filimon A; Zurac SA; Milac AL; Sima LE; Petrescu SM; Negroiu G
Melanoma Res; 2014 Jun; 24(3):219-36. PubMed ID: 24709887
[TBL] [Abstract][Full Text] [Related]
33. Expression of cyclo-oxygenase-2 in macrophages associated with cutaneous melanoma at different stages of progression.
Bianchini F; Massi D; Marconi C; Franchi A; Baroni G; Santucci M; Mannini A; Mugnai G; Calorini L
Prostaglandins Other Lipid Mediat; 2007 Jun; 83(4):320-8. PubMed ID: 17499752
[TBL] [Abstract][Full Text] [Related]
34. Human melanoma cells express FGFR/Src/Rho signaling that entails an adhesion-independent caveolin-1 membrane association.
Fecchi K; Travaglione S; Spadaro F; Quattrini A; Parolini I; Piccaro G; Raggi C; Fabbri A; Felicetti F; Carè A; Fiorentini C; Sargiacomo M
Int J Cancer; 2012 Mar; 130(6):1273-83. PubMed ID: 21445970
[TBL] [Abstract][Full Text] [Related]
35. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth.
Niu G; Bowman T; Huang M; Shivers S; Reintgen D; Daud A; Chang A; Kraker A; Jove R; Yu H
Oncogene; 2002 Oct; 21(46):7001-10. PubMed ID: 12370822
[TBL] [Abstract][Full Text] [Related]
36. Lipocalin-type prostaglandin D synthase as a marker for the proliferative potential of melanocyte-lineage cells in the human skin.
Shimanuki M; Takeda K; Kawaguchi M; Suzuki T; Shibahara S
J Dermatol; 2012 Aug; 39(8):699-704. PubMed ID: 22299829
[TBL] [Abstract][Full Text] [Related]
37. Tumor-associated cysteine proteinase activities in human melanoma cells and fibroblasts of different origin.
Mayer P; Schmid H; Schaber B; Fierlbeck G
Eur J Cell Biol; 1997 Aug; 73(4):344-51. PubMed ID: 9270877
[TBL] [Abstract][Full Text] [Related]
38. Tyrosinase activity in serum from patients with malignant melanoma.
Agrup P; Carstam R; Wittbjer A; Rorsman H; Rosengren E
Acta Derm Venereol; 1989; 69(2):120-4. PubMed ID: 2564228
[TBL] [Abstract][Full Text] [Related]
39. mTOR is activated in the majority of malignant melanomas.
Karbowniczek M; Spittle CS; Morrison T; Wu H; Henske EP
J Invest Dermatol; 2008 Apr; 128(4):980-7. PubMed ID: 17914450
[TBL] [Abstract][Full Text] [Related]
40. Elevated expression of protein tyrosine kinase c-Yes, but not c-Src, in human malignant melanoma.
Loganzo F; Dosik JS; Zhao Y; Vidal MJ; Nanus DM; Sudol M; Albino AP
Oncogene; 1993 Oct; 8(10):2637-44. PubMed ID: 7690926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
